Adjuvant chemotherapy for non-organ confined disease after radical cystectomy

Of 50 patients with pT3b, pT4 and/or pN+ disease after cystectomy, 27 were administered adjuvant four cycles of cisplatin, methotrexate and vinblastine (CMV) and 23 were followed expectantly (no-treatment group). Median follow-up was 14 months in CMV group and 11 months in no-treatment group. Median recurrence-free survival was 21 months in CMV group and 17 months in no-treatment group (p = 0.573). Median overall survival was 41+ months in CMV group and 84+ months in no-treatment group, respectively (p = 0.501). In our experience, adjuvant chemotherapy after cystectomy seemed not to provide a survival advantage.